0000950170-24-026607.txt : 20240305
0000950170-24-026607.hdr.sgml : 20240305
20240305200007
ACCESSION NUMBER: 0000950170-24-026607
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rodino-Klapac Louise
CENTRAL INDEX KEY: 0001836218
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14895
FILM NUMBER: 24723766
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: STE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc.
CENTRAL INDEX KEY: 0000873303
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 930797222
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-274-4000
MAIL ADDRESS:
STREET 1: 215 FIRST STREET
STREET 2: SUITE 415
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Sarepta Therapuetics, Inc.
DATE OF NAME CHANGE: 20120712
FORMER COMPANY:
FORMER CONFORMED NAME: AVI BIOPHARMA INC
DATE OF NAME CHANGE: 19980930
FORMER COMPANY:
FORMER CONFORMED NAME: ANTIVIRALS INC
DATE OF NAME CHANGE: 19970123
4
1
ownership.xml
4
X0508
4
2024-03-01
0000873303
Sarepta Therapeutics, Inc.
SRPT
0001836218
Rodino-Klapac Louise
215 FIRST STREET
SUITE 415
CAMBRIDGE
MA
02142
false
true
false
false
Head of R&D, CSO
false
Common Stock
2024-03-01
4
F
false
778
126.19
D
65222
D
Common Stock
2024-03-01
4
A
false
6000
0
A
71222
D
Stock Option (right to buy)
128.67
2024-03-01
4
A
false
12500
0
A
2025-03-01
2034-03-01
Common Stock
12500
12500
D
Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020.
Amount of Securities Beneficially Owned includes 249 shares purchased under the Company's registered Employee Stock Purchase Plan on February 29, 2024.
The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date.
Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter.
/s/ Ryan Brown, as Attorney-in-Fact for Louise Rodino-Klapac
2024-03-05